Funding

Washington-Based BrainChild Bio Raises $116M in Series A Financing

Sep 9, 2026 | By Devin Jacobs

SUMMARY

BrainChild Bio raised $116M in Series A funding.
The funding will support its cancer drug trials.
BrainChild develops CAR T-cell therapies for brain tumors.

BrainChild Bio, a Seattle, WA-based provider of CAR T-cell therapies to treat tumors in the central nervous system, has raised $116M in a Series A funding round led by an undisclosed private family fund and foundation.

The round also saw participation from Seattle Children’s and WRF Capital.

The company will use the funding to support the ILLUMINATE Phase 2 study of BCB-276 for diffuse intrinsic pontine glioma (DIPG) and continue development of BCB-214, a triple-targeting CAR T cell therapy for glioblastoma.

Funding Snapshot

Metric	Details
Fundraise Amount	$116 million
Funding Round	Series A
Lead Investor	Undisclosed private family fund and foundation
Company	BrainChild Bio
Sector	Biotechnology & Cell Therapy
Headquarters	Seattle, Washington, USA

RECOMMENDED FOR YOU

Funding

[Funding alert] GA-based Arglass Raised Over $230Million in Funding

Devin Jacobs

Feb 7, 2024

Startup News

SAP Acquires Reltio

Devin Jacobs

Mar 28, 2026

Startup News

Arima Genomics Announces Distribution Partnership with Active Motif

Devin Jacobs

Jul 3, 2026

About BrainChild Bio

Founded by Michael Jensen, BrainChild Bio is a kids-first, clinical-stage biotechnology company developing CAR T cell therapies for tumors in the central nervous system. Its platform combines synthetic biology, multiplex targeting, CAR T cell engineering, delivery technologies and streamlined manufacturing.

Core offerings include:

CAR T cell therapies
CNS tumor treatments
Multiplex tumor targeting
CAR T cell delivery and manufacturing technologies

Core Technologies / Products / Services

Capability/Product	Application/Use Case
BCB-276	CAR T therapy being studied for DIPG
BCB-214	Triple-targeting CAR T therapy for glioblastoma
Locoregional delivery	Direct delivery of CAR T cells into cerebrospinal fluid
Multiplex targeting	Targeting multiple tumor antigens

Leadership Comments

“This financing enables us to chart our path forward to serve the children and families afflicted with devastating brain tumors and represents a new paradigm for treating CNS brain tumors in children and adults,” stated Michael Jensen, MD, Founder and Chief Scientific Officer of BrainChild Bio.

“Our path to building BrainChild Bio has led us to secure the support of a unique and committed syndicate of investors who share our mission to prioritize therapeutic innovation for children with cancer, while also rapidly advancing new science that can change the course of brain cancers for a wider population,” said Steven Brugger, Chief Executive Officer of BrainChild Bio.